- Home
- BRAG vs SLN Comparison
BRAG vs SLN Comparison
Compare BRAG & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRAG
- SLN
- Stock Information
- Founded
- BRAG 2018
- SLN 1994
- Country
- BRAG Canada
- SLN United Kingdom
- Employees
- BRAG N/A
- SLN N/A
- Industry
- BRAG Office Equipment/Supplies/Services
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- BRAG Technology
- SLN Health Care
- Exchange
- BRAG Nasdaq
- SLN Nasdaq
- Market Cap
- BRAG 117.8M
- SLN 123.3M
- IPO Year
- BRAG N/A
- SLN N/A
- Fundamental
- Price
- BRAG $3.73
- SLN $3.14
- Analyst Decision
- BRAG Strong Buy
- SLN Buy
- Analyst Count
- BRAG 3
- SLN 5
- Target Price
- BRAG $7.33
- SLN $40.80
- AVG Volume (30 Days)
- BRAG 55.0K
- SLN 292.1K
- Earning Date
- BRAG 05-08-2025
- SLN 05-15-2025
- Dividend Yield
- BRAG N/A
- SLN N/A
- EPS Growth
- BRAG N/A
- SLN N/A
- EPS
- BRAG N/A
- SLN N/A
- Revenue
- BRAG $105,602,029.00
- SLN $43,258,000.00
- Revenue This Year
- BRAG $16.92
- SLN N/A
- Revenue Next Year
- BRAG $9.87
- SLN N/A
- P/E Ratio
- BRAG N/A
- SLN N/A
- Revenue Growth
- BRAG 9.07
- SLN 36.71
- 52 Week Low
- BRAG $2.86
- SLN $1.97
- 52 Week High
- BRAG $6.70
- SLN $24.38
- Technical
- Relative Strength Index (RSI)
- BRAG 42.28
- SLN 49.25
- Support Level
- BRAG $3.50
- SLN $2.63
- Resistance Level
- BRAG $3.75
- SLN $2.95
- Average True Range (ATR)
- BRAG 0.23
- SLN 0.43
- MACD
- BRAG 0.00
- SLN 0.11
- Stochastic Oscillator
- BRAG 39.51
- SLN 72.67
About BRAG Bragg Gaming Group Inc.
Bragg Gaming Group Inc is predominantly a B2B online gaming technology platform and casino content aggregator. The Company's proprietary studios offer high-performing, data-driven casino gaming titles from in-house brands Wild Streak, Spin, Atomic Slot Lab, Indigo Magic and Oryx Gaming. It offers a full range of games including slot games, table games, card games, video bingo, scratch card games, virtual sports, and live dealer games which are featured on the company's PAM platform and also available for use on other gaming platforms offered by third parties. Geographically, the company generates a majority of its revenue from the Netherlands and the rest from Curacao, Malta, United States, Croatia, and other regions.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.